^
Association details:
| Biomarker: | BCL2 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
3102 - Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia
Published date:
03/10/2021
Excerpt:
...mutant forms of BCL2 identified in CLL cells of pts with PD on V-Rx, and reducing venetoclax-binding to BCL2, were significantly more effective in protecting MEC1-ROR1 cells than MEC1 cells from the cytotoxic effects of venetoclax in vitro.
